Advanced Search
Contact | Corporate | Help

Prospective Trial of Rituximab for Primary Pulmonary Alveolar Proteinosis

Sponsors:
  • East Carolina University
  • Genentech
Phases:
  • Phase II
IndicationsAcronym:
PAP
  • Pulmonary Alveolar Proteinosis
  • Primary Disease
Age Groups:
  • Adult
  • Senior
Gender:
Both
Names:
  • Drug: rituximab
Enrollment:
10

Additional information about NCT00552461.


SourceSolution © 2008-2012